BioXcel Therapeutics, Inc. (BTAI)

Market Cap	805.53M
Revenue (ttm)	137,000
Net Income (ttm)	-137.07M
Shares Out	28.02M
EPS (ttm)	-4.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	121,768
Open	28.29
Previous Close	28.52
Day's Range	27.57 - 28.88
52-Week Range	8.80 - 32.96
Beta	1.15
Analysts	Buy
Price Target	48.59 (+69.07%)
Earnings Date	Mar 9, 2023

About BTAI

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acu...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 8, 2018
• Employees: 89
• Stock Exchange: NASDAQ
• Ticker Symbol: BTAI

Analyst Forecast

According to 16 analysts, the average rating for BTAI stock is "Buy." The 12-month stock price forecast is $48.59, which is an increase of 69.07% from the latest price.

Price Target

$48.59

(69.07% upside)

Analyst Consensus: Buy